The Latin America, Middle East and Africa Filgrastim Market would witness market growth of 8.9% CAGR during the forecast period (2021-2027).
Filgrastim is also utilized to boost white blood cells after chemotherapy or radiation therapy for cancer patients and to decrease the chances of infection at the time of stem cell transplantation. Furthermore, filgrastim biosimilar treatment is performed to support the bone marrow to generate more neutrophils (white blood cells) that would help in fighting against the infection in patients who are undergoing chemotherapy for cancer treatment.
In the case of cancer, a patient gets cancer medicines that help them to fight cancer cells, but these medicines can also negatively impact the white blood cells, which fight against infections. Due to this, patients would need filgrastim to help in preventing or reducing the risk of infections at the time, when patients are treated with cancer medicines. By using filgrastim medicine, the bone marrow of a patient would recover soon after bone marrow transplantation, for a procedure that is known as peripheral blood. It also helps in enhancing the survival of cancer patients who were exposed to radiation.
The Middle East region has a relatively stronger healthcare system and the governments across this region have also allotted a huge amount of their budget on building a better healthcare system, which is estimated to create lucrative opportunities for the regional market players. Additionally, the presence and entrance of many market players are also supporting the growth of the regional filgrastim market over the forecast period.
The abundant availability and accessibility of filgrastim in this region are estimated to fuel the regional market growth. Also, the increasing cases of cancer, the growing geriatric population, and the supportive reimbursement policies in the developed nations of the region would augment the overall growth of the regional market. However, the underdeveloped nations of this region may not contribute significantly to the overall growth of the regional filgrastim market in the forecast years.
The Brazil market dominated the LAMEA Filgrastim Market by Country in 2020, and would continue to be a dominant market till 2027; thereby, achieving a market value of $19.2 million by 2027. The Argentina market is estimated to grow at a CAGR of 9.8% during (2021 - 2027). Additionally, The UAE market would witness a CAGR of 8.4% during (2021 - 2027).
Based on Drug Type, the market is segmented into Biosimilar and Biologic. Based on Indication, the market is segmented into Chemotherapy induced Neutropenia, Chronic Neutropenia and Other Indications. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
Free Valuable Insights: The Global Filgrastim Market is Predict to reach $953.4 million by 2027, at a CAGR of 8%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Amgen, Inc., Pfizer, Inc., Novartis AG, Dr. Reddy’s Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Kyowa Kirin Co., Ltd. (Kirin Company), Cadila Healthcare Ltd. (Zydus Cadila), Apotex, Inc., and Toksöz Group
By Drug Type
By Indication
By Distribution Channel
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 